Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Dianthus Therapeutics, Inc. /DE/ (DNTH)

Dianthus Therapeutics Q3 net loss widens to $46.6 million; cash about $1.2 billion

Mixed Impact 3 of 5 earnings Written later

Dianthus Therapeutics reported a third-quarter 2026 net loss of $46.6 million, or $0.81 per share, up from $36.8 million, or $0.97 per share, a year earlier. Higher research and development and general and administrative costs drove the increase, while the company reported about $1.2 billion in cash, cash equivalents and investments as of September 30, 2026, which it projects will fund operations into 2030.

Key points

  • Q3 2026 net loss was $46.6 million, or $0.81 per share, versus $36.8 million, or $0.97 per share, in Q3 2025.
  • R&D expenses rose to $45.6 million from $32.5 million, mainly on higher clinical costs and headcount.
  • G&A expenses rose to $14.1 million from $8.2 million, mainly due to increased headcount.
  • Phase 2 MoMeNtum top-line results for claseprubart in MMN are expected in December 2026.

The filing

CompanyDianthus Therapeutics, Inc. /DE/ (DNTH)
Form8-K, current report
Filed with the SECNov 4, 2026, 4:03 PM ET
Accession number0001690585-26-000039

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 04, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.